Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized or requiring admission to hospital for management of acute heart failure within the previous 48 hours.~* Pulmonary wedge pressure above or equal to18 mmHg determined by right heart catheterization~Exclusion Criteria:~* Systolic blood pressure below 115 mmHg~* Significant valvular diseases or arrythmias~* Acute coronary syndrome in previous 45 days~* Treatment with mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device)~* Impaired renal or hepatic function~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 87 Years
- Healthy Volunteers: f

Study Arms:
- RLX030 (Type: EXPERIMENTAL): RLX030 as intravenous infusion for 20 hours
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo as intravenous infusion for 20 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).